Table 1.
Summary of the prevention strategies of TRALI.
| Disease | Strategy | Type of study | Effects | Country | Year | Sources | ||
|---|---|---|---|---|---|---|---|---|
| Antibody dependent TRALI |
Donor management |
Male-only plasma | Retrospective study | Decline in TRALI | Australia | 2022 | Sivakaanthan et al. (21) | |
| Retrospective study | No TRALI cases reported | UK | 2017 | Bolton-Maggs et al. (110) | ||||
| Male-dominate plasma | Retrospective study | Decline in TRALI | Australia | 2022 | Sivakaanthan et al. (21) | |||
| Exclusion of allo-exposure donors | Prospective study | Decline in TRALI | Netherlands | 2012 | Middelburg et al. (111) | |||
| Screening for antibodies | Retrospective study | Decline in TRALI | Germany France UK Sweden USA |
2012 | Reesink et al. (112) | |||
| SDP | Clinical study | No cases of TRALI | Norway | 2003 | Flesland et al. (113) | |||
| Systematic review and meta-analysis | No cases of TRALI | Netherlands | 2017 | Saadah et al. (114) | ||||
| Clinical study | No cases of TRALI | Netherlands | 2020 | Saadah et al. (115) | ||||
| Retrospective study | TRALI occurrence | Netherlands | 2022 | Klanderman et al. (20) | ||||
| Case series | TRALI occurrence | Netherlands | 2022 | Klanderman et al. (116) | ||||
| Antibody independent TRALI |
Leukoreduction | Retrospective study | Decline in TRALI | USA | 2010 | Blumberg et al. (117) | ||
| Preclinical study | TRALI mitigation | USA | 2014 | Silliman et al. (47) | ||||
| Preclinical study | TRALI mitigation | USA | 2020 | McQuinn et al. (118) | ||||
| Systematic review | Invalid in prevention TRALI | Ecuador | 2015 | Simancas-Racines et al. (119) | ||||
| PRT | Mirasol | Preclinical study | Invalid in prevention TRALI | USA | 2010 | Silliman et al. (120) | ||
| Mirasol | Preclinical study | Incapable of inducing TRALI | USA | 2015 | Caudrillie et al. (121) | |||
| Mirasol | Preclinical study | Incapable of inducing TRALI | USA | 2017 | Mallavia et al. (122) | |||
| Mirasol | Retrospective study | Valid in prevention TRAL | Ghana | 2019 | Owusu-Ofori et al. (123) | |||
| Intercept (TM) | Prospective study | No TRALI cases | Italy | 2015 | Knutson et al. (124) | |||
| Intercept (TM) | Cohort study | No effect on prevention TRALI | USA | 2022 | Snyder et al. (125) | |||
| PAS | Review | Reducing the incidence of TRALI | USA | 2019 | Kuldanek et al. (126) | |||
| Review | Reducing the incidence of TRALI | Netherlands | 2018 | van der Meer et al. (127) | ||||
| TRALI | PBM | Review | Decreasing the incidence of TRALI | USA | 2017 | Friedman et al. (128) | ||
| Retrospective study | Decline the incidence of TRALI | Austria | 2019 | Tung et al. (129) | ||||
| Retrospective study | Avoiding TRALI occurrence | Sri Lanka | 2022 | Priyanjani et al. (130) | ||||
TRALI, transfusion-related acute lung injury; SDP, solvent/detergent treated pooled plasma; PRT, pathogen reduction technology; PAS, platelet additive solution; PBM, patient blood management.